Because pancreatic NETs generally have a much better prognosis than other cancers of the pancreas, their inclusion in the same category as the other pancreatic cancers — namely, in the same group as pancreatic adenocarcinomas — may mean that calculation of the survival rate for pancreatic cancer of any type could be skewed. Read more . . .
The incidence of age-adjusted pancreatic neuroendocrine tumors (NETs) rose annually by 6.7% from 1995 to 2007 and by 13.4% from 2008 to 2014 (P < .05) among patients across the Surveillance, Epidemiology, and End Result (SEER) registries following revisions in 2000 and 2010 to the way NETs are characterized.